GHSR and breast cancer: Similarly, the sensitivity to BC at Ta stage is at 63.0% (34/54), also lower than most of the published results for multigene panels (95% (Ta/T1) for GHSR/MAL, 64.5% for OTX1/SOX1-OT, 83.3% for ONECUT2/VIM, and 51.9% for EpiCheck [23]), but higher than cytology (22.2–41.2%), FISH (44.4–52.9%), and FDA-approved NMP22 test (39–51%) [42].